Aditum Bio

Hubpay is an independently regulated provider of cross-border money services designed to increase financial inclusion in emerging markets. It utilizes data science to create accessible, practical, and affordable everyday financial solutions delivered responsibly to everyone, regardless of income level.

Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses, and rhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The company targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.

Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults. Versanis Bio is advancing Bimagrumab, a human monoclonal antibody to the activin type II receptors that block the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies, Bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.

Anteris Bio is developing a new therapy for the treatment of renal disease.